AION Biosystems has announced a significant advancement in cancer care with TempShield™, an AI-powered wearable thermometer that has demonstrated a 90% reduction in mortality and a 79% decrease in inpatient days for chemotherapy patients. These findings, revealed at the 2025 ASCO Annual Meeting, represent the first validated long-term temperature monitoring in outpatient oncology, promising earlier infection detection and improved patient outcomes.
The Infection Crisis in Cancer Care
- Infections cause over 50% of cancer patient deaths, especially in hematologic and solid tumor cancers.
- Up to 40% of chemotherapy patients halt treatment early due to infection complications.
- Current temperature monitoring is reactive, relying on patient-reported fever symptoms, often too late for effective intervention.
TempShield™ Breakthrough and Study Details
- Conducted at Roswell Park Cancer Care Network and funded by New York’s Stay Well Program.
- Patients wore TempShield for an average of 120 days — the longest outpatient temperature monitoring to date.
- TempShield offers continuous, 24/7 temperature tracking with real-time alerts to clinicians, often detecting fevers 72+ hours before symptoms.
Key Outcomes Among Chemotherapy Patients
- 90% reduction in mortality rates.
- 79% reduction in inpatient days and 52% shorter hospital stays.
- Early fever detection enabling timely clinical intervention.
Broader Implications for Patient Care
- Benefits extend beyond high-risk patients to all chemotherapy recipients.
- Potential to disrupt the infection-treatment interruption cycle by enabling early care.
- Could reduce hospital burden and improve survival across oncology.
Real-World Impact and Patient Experience
- 99% insurance reimbursement eligibility; over half pay no copay.
- Positive patient testimony highlights life-saving impact.
- Mirrored success in large oncology groups such as NY Cancer and Blood with 2,000+ patients.
Industry Firsts and Technology Integration
- First FDA-cleared wearable thermometer for oncology patients.
- Largest deployment of a wearable thermometer in chemotherapy patients.
- Integrated into Flatiron Health’s OncoEMR, the leading oncology-specific electronic health record (EHR).
TempShield™ represents a revolutionary leap in cancer care by enabling proactive infection monitoring through AI-powered continuous temperature tracking. This device not only dramatically reduces mortality and hospitalizations but also redefines standard oncology patient care by catching infections before symptoms arise. As healthcare providers adopt TempShield, chemotherapy patients gain a critical head start against one of cancer care’s deadliest complications.
